Wegovy Weight Loss Drug: Price In India, Doses, How Does It Work And More

Danish pharmaceutical company Novo Nordisk on Tuesday launched its weight-loss drug Wegovy in India.

Wegovy, a once-weekly GLP-1 receptor agonist, is India’s first approved drug for both long-term weight management and reducing the risk of major cardiovascular events in certain patients. 

Starting at Rs 17,300, Wegovy is a once-weekly injectable containing semaglutide. It is available in five dosing strengths and comes with an easy-to-use pen device. The drug is approved for long-term weight management and also helps reduce the risk of major cardiovascular events in people with obesity-related conditions.

Wegovy will be offered in five strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. According to Novo Nordisk, the initial three doses are priced at Rs 4,336 each. The total monthly treatment cost comes to around Rs 17,345.

This price point aligns closely with the pricing of Eli Lilly’s weight-loss drug, Mounjaro. 

Meanwhile, the 1.7 mg dose is priced at Rs 24,280 per pen and the 2.4 mg dose is priced at Rs 26,015 per pen.

Wegovy contains semaglutide, a GLP-1 receptor agonist. Once injected, the dose from the innovative pen device targets areas of the brain that control appetite and food intake. This helps in reducing hunger, increasing fullness and curbing cravings, leading to weight loss. 

It also improves insulin sensitivity and supports heart health by lowering cardiometabolic risks. Unlike Ozempic, which is used for type 2 diabetes, Wegovy is approved for weight management and cardiovascular risk reduction in people with obesity or overweight and existing heart disease.

"Obesity is not just a personal health concern, it is a chronic disease and a national epidemic that India cannot afford to ignore. Recognising this, we are proud to announce that we are bringing Wegovy to Indians as a transformative and evidence-based therapeutic solution with the convenience of a world-class, state-of-the-art pen device," said Vikrant Shrotriya – Managing Director, Novo Nordisk India.